While patient-prosthesis mismatch (PPM) is known to be an adverse risk after AVR, few studies have addressed the effect of PPM on valve durability. This study evaluates the role of valve size and hemodynamics on long term durability after AVR with a Magna bioprosthesis. Methods: We performed...
结果发现,在调整了高血压、中风等混杂变量后,胺碘酮在大多数手术类型中都是延迟拔管的风险因素 。像单纯冠状动脉旁路移植术(Isolated CABG)、主动脉瓣置换术(AVR)或二尖瓣置换术(MVR)以及其他手术类型中,胺碘酮都被 “揪出来” 是风险因素 。不过在 AVR + MVR、瓣膜手术 + CABG 和胸主动脉手术中,没有发现胺碘酮...
CARDIAC SURGERYWe have reviewed 665 patients in whom the standard Hancock porcine bioprosthesis (HPB) was used for aortic (AVR = 173), mitral (MVR = 437), and mitral and aortic (MAVR = 55) valve replacement in the time interval from 1970 to 1983. After AVR, HPB-related deaths occurred...
From January 2006 to December 2008, 693 patients underwent aortic valve replacement (AVR) in our institution. All patients receiving a Carpentier-Edwards Perimount (Edwards Lifesciences, Irvine, CA) or Freedom Solo (Sorin Group, Saluggia, Italy) pericardial prosthesis were retrospectively identified....
Methods We performed a singleヽenter retrospective analysis of 203 patients consecutively undergoing isolated AVR between March 2016 and June 2018 with the right minithoracotomy approach and our modified technique of central cannulation. Aortic valve diseases were stenosis (89.9%), regurgitation (1.6%),...
813 patients underwent aortic (AVR) or mitral valve replacement using the Carpentier-Edwards bioprosthesis from 1976 to 1983. Operative mortality was 5.49%... G Soots,A Pieronne,JP Roux,... - 《European Heart Journal》 被引量: 20发表: 0年 加载更多来源...
cardiac solutions in the aortic and mitral field,” said Brian Duncan, M.D., Vice President, Medical Affairs, Cardiac Surgery at LivaNova. “Also, as we celebrate the 10thanniversary of Perceval’s introduction into the AVR treatment process, we are...
the 23 mm Sapien™ XT seems to be the most useful TAVI valve because it fits within the majority of currently used bioprostheses (23 mm and the 25 mm diameter). We suggest implanting large bioprosthesis during first-time standard AVR in order to prevent size mismatch in case of future ...
Fig. 1. Survival function: Top, After AVR; bottom, after MVR. Clinical improvement Before implantation of the Mosaic bioprosthesis, 79.0% of the patients with aortic valve lesions and 81.0% of those with mitral valve lesions were classified in New York Heart Association (NYHA) classes III and...
The probability of freedom of thromboembolism of the new flexible stent series (247 patients) at 48 months is 90.92% for MVR, 96.6% for AVR and 100% for MVR + AVR. for the entire series of patients (rigid/flexible stents) at 6 years is low: the linearized incidence for both MVR and ...